Vir Biotechnology Inc. (VIR) Misses Q4 EPS by 41c

Vir Biotechnology Inc. (NASDAQ: VIR) reported Q4 EPS of ($0.76), $0.41 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $49.4 million versus the consensus estimate of $149.6 million.

For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• JPMorgan Downgrades HCL Technologies (HCLT:IN) to Underweight
• BofA lists top 5 themes driving next $1tn in incremental semi sales